Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/III Study of Suvemcitug Plus Trifluridine/Tipiracil Tablets (FTD/TPI) Versus Placebo Plus Trifluridine/Tipiracil Tablets in Participants With Refractory Metastatic Colorectal Cancer

NCT07361003 is registered in ClinicalTrials.gov with Jiangsu Simcere Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07361003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07361003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/III Study of Suvemcitug Plus Trifluridine/Tipiracil Tablets (FTD/TPI) Versus Placebo Plus Trifluridine/Tipiracil Tablets in Participants With Refractory Metastatic Colorectal Cancer
Lead sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
November 12, 2025
Completion date
July 31, 2028
Enrollment
464 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

refractory metastatic colorectal cancer